Phase 1 Type 1 Diabetes Trial, Recruiting NCT07539415 Sponsor: Daewoong Pharmaceutical Co. LTD. Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Phase 1 Type 1 Diabetes Trial, Recruiting

NCT07539415
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 19 to 65 years old at the time of screening who are generally healthy.
  • People whose body weight is between 50.0 kg and 100.0 kg, and whose Body Mass Index (BMI) is between 20.0 and 29.9 kg/m² at screening.
  • People who have no birth defects, no ongoing conditions requiring treatment, and no concerning symptoms or findings found during a medical check-up.
  • People whose blood tests, vital signs, physical examination, and heart trace (ECG) results are considered suitable for this trial based on the trial's requirements.
  • People who have chosen to take part voluntarily and have signed a written consent form after being fully informed about the trial and what it involves.

Who may not be able to join:

  • People who have a past or current history of significant medical conditions affecting the liver, kidneys, nervous system, mental health, lungs, hormones, blood, cancer, urinary or reproductive system, heart, digestive system, or muscles and bones.
  • People who are pregnant (confirmed by a blood test) or currently breastfeeding.
  • People who have had a serious allergic reaction (such as severe swelling or anaphylaxis) to the trial medication, its ingredients, or similar medications (such as GLP-1 receptor agonist drugs).
  • People who have a history of skin conditions (such as burns or skin cancer) or skin transplant surgery that could affect how the trial medication is absorbed through the skin.
  • People who have a history of acute or long-term inflammation of the pancreas (pancreatitis).
  • People who have a personal or family history of a specific type of thyroid cancer (medullary thyroid cancer) or a condition called Multiple Endocrine Neoplasia type 2 (MEN2).
  • People the trial doctor considers unsuitable for reasons beyond the criteria listed above.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8225508317

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Daewoong Pharmaceutical Co. LTD.
Registry
ClinicalTrials.gov
Start date
6 May 2026
Est. completion
27 October 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

AUC 0-t; Cmax

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov